TitleDifferentiation therapy for IDH1/2 mutant malignancies.
Publication TypeJournal Article
Year of Publication2013
AuthorsGarrett-Bakelman, Francine E., and Melnick Ari M.
JournalCell Res
Volume23
Issue8
Pagination975-7
Date Published2013 Aug
ISSN1748-7838
Abstract

<p>Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietic and glial cells. Two recent reports in Science describe the first IDH1 and IDH2 mutant-specific small-molecule inhibitors, which induce cell differentiation of myeloid leukemias and malignant gliomas.</p>

DOI10.1038/cr.2013.73
Alternate JournalCell Res
PubMed ID23732524
PubMed Central IDPMC3731561